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Introduction and aims. Balanced propofol sedation (BPS) administered by gastroenterologists has gained popularity in endoscopic
procedures. Few studies exist about the safety of this approach during endosonography with fine needle aspiration (EUS-FNA).
We assessed the safety of BPS in EUS-FNA. Materials and methods. 112 consecutive patients, referred to our unit to perform EUS-
FNA, from February 2008 to December 2009, were sedated with BPS. A second gastroenterologist administered the drugs and
monitorized the patient. Results. All the 112 patients (62 males, mean age 58.35) completed the examination. The mean dose of
midazolam and propofol was, respectively, of 2.1mg (range 1–4mg) and 350mg (range 180–400). All patients received oxygen
with a mean flux of 4 liter/minute (range 2–6 liters/minute). The mean recovery time after procedure was 25 minutes (range 18–45
minutes). No major complications related to sedation were registered during all procedures. The oxygen saturation of all patients
never reduced to less than 85%. Blood systolic pressure during and after the procedure never reduced to less than 100mmHg.
Conclusions. In our experience BPS administered by non-anaesthesiologists provided safe and successful sedation in patients
undergoing EUS-FNA.
1. Background
Propofol is a short-acting sedative, agonist of γ-aminobu-
tyric acid receptor in the central nervous system [1]. Its
use has principally been limited to anesthesiologists for the
induction and maintenance of deep sedation in patients
undergoing surgical procedures. Recently propofol use has
extended to sedation in endoscopic procedure, administered
by anesthesiologists or by gastroenterologists [2].
Propofol administered by nonanesthesiologists has
shown to be safe for an upper endoscopy, a colonoscopy, and
advanced endoscopic procedures, such as an ERCP and an
EUS [3]. For endoscopic procedures the use of midazolam,
with or without meperidine, in combination with propofol
is called balanced propofol sedation (BPS). It has been
shown that BPS compared to propofol alone decreases total
propofol doses required and increases patient comfort [4–6].
2. Aim of the Study
The purpose of this preliminary study was to assess safety
and feasibility of gastroenterologist-administered BPS for
operative upper EUS in a tertiary referral center with a pre-
viously established program for colonoscopy sedation with
propofol.
3. Patients and Methods
The study received approval from our institutional review
board. From February 2008 to December 2009 patients who
presented at our unit for an operative EUS were eligible for
the study if they were age 18 years or older, American Society
of Anesthesiology (ASA) class I or II, and capable to provide
written informed consent for study participation. Exclusion
criteria were inability to provide informed consent, history of
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Table 1: Baseline population characteristics.
Age, median years (range) 58 (25–86)
Male/female 62/50
ASA grade
Class I 68
Class II 34
Indication for FNA
Mediastinal nodes 26
Submucosal lesion 14
Pancreatic mass 72
Needle passes (range) 3 (2–5)
Baseline hemodynamics, median (range)
Mean blood pressure mmHg 125 (85–168)
Pulse, per minute 71 (48–90)
SaO2, % 96 (94–100)
ASA, American Society of Anesthesiologists’ grade.
allergic reactions or hypersensitivities to midazolam, propo-
fol, eggs, or soybeans, high-risk head and neck anatomy
(Mallampati > 2) that may complicate airway rescue, sleep
apnea syndrome, and ASA class > II.
Patients underwent BPS administered by a gastroenterol-
ogist who was not involved in the endoscopic procedure. The
physicians administering sedation were certified in advanced
cardiac life support (ACLS) and had successfully completed
an intensively structured training program also in the use of
laryngeal mask. An anesthesiologist was on call during the
procedure. After a single dose of midazolam (0.05mg/Kg),
a starter bolus of 0.5mg/kg of propofol was administered.
Repeated boluses of 10 to 20mg of propofol were than
administered on demand with a 1- to 2-minute interval for
the whole time of the procedure. Propofol boluses frequency
and dose were titrated on the patient response, including
vital signs and manifestations of restlessness or discomfort.
The maximum dose allowed to be administered was 400mg.
Baseline vital signs (heart rate, blood pressure, and oxy-
gen saturation) were obtained in all patients before induction
of sedation. Throughout the procedure, all patients received
oxygen 4 L/min by nasal cannula. Continuous pulse oximetry
and end-expiratory carbon dioxide (EECO2) was monitor-
ized. Blood pressure was measured every 5 minutes.
The following parameters were recorded: patient demo-
graphics, procedure indication and duration, EUS findings,
midazolam dose, propofol dose, and number of FNA
passes. The baseline values and changes in vital signs or
oxygen saturation (SpO2) from the baseline were recorded.
Complications were recorded, including hypoxia, defined
as a reduction in oxygen saturation to less than 85% for
more than 20 seconds, use of supplemental oxygen (O2) by
nasal cannula (NC) in excess of 4 L/min, positive pressure
ventilation (PPV) or laringeal mask use, hypotension, brady-
cardia. EUS was performed by one experienced endosono-
grapher who had practiced for 2 years after completing a
therapeutic endoscopy fellowship and performed over 500
EUS procedures yearly. The echoendoscope was inserted
once the patient was responsive only to mild prodding and
the tongue was flaccid to manual palpation. EUS-guided
FNA (EUS-FNA) was carried out in a standard fashion by
using a 22-gauge needle. After the procedure, the patients
were transported to the recovery roomwhere blood pressure,
SpO2, and heart rate were measured continuously until
discharge. Discharge was possible when Glasgow Coma Scale
score of the patient was >9 and OSSA scale was 5 (see
Table 2).
4. Results
Between February 2008 and December 2009, 253 consecutive
patients were considered for enrollment. Among these, 53
patients were excluded because their asa class was III,
34 patients were excluded because their Mallampati score
was more than 2, 10 because of a history of sleep apnea
syndrome, 44 patients refused to provide informed consent
to participate in the study. Overall 112 patients were included
in the study. Demographic and baseline characteristics of the
patients are shown in Table 1, as well as indications for EUS-
FNA. The most common indication was the evaluation of
a known or suspected pancreatic mass or cyst. The mean
dose of propofol given was 350mg (range 180–400mg), and
the mean dose of midazolam was 2.1mg (range 1–4mg).
All patients received supplemental oxygen in nasal cannula
at the mean flux of 5 L/min. The mean procedure time in
our study was 42.96 ± 15min. A mean of 3 passes of EUS-
FNA was performed (range 2–5). The accuracy of EUS-
FNA was 75.3%. One endoscopic complication occurred
(0.9%), a perforation of the duodenal bulb in a patient
with a pseudodiverticulum of the bulb subsequent to an
ulcer. After an attempt of conservative management with
the positioning of a nasogastric drainage, total parenteral
nutrition and intravenous antibiotic therapy the patient was
referred to the surgical unit because of peritonism. The
patient is doing well after 3 months of followup. In 5 patients
(4.5%) the blood pressure reduced to less than 90mmHg
during an interval of time between two measurements (10
minutes). Administering fluids allowed a rapid increase of
the blood pressure above the target value. In 3 patients
(2.7%) the heart rate decreased to less than 50 pulses per
minute for more than 1 minute. With the administration of
intravenous buscopan, the heart rate rose back to more than
50 pulses per minute in few seconds in all these patients. In 5
patients (4.5%) oxygen saturation decreased to less than 90%
while they were receiving oxygen with a 4 L/min flux. Two
patients rapidly recovered increasing in the flux to 8 L/min,
two patients needed mask ventilation for few minutes with
complete recovery of a normal blood oxygenation, but this
event required the stop of the procedure that was completed
with anesthesiological assistance. In one patient (0.9%) the
insertion of a laryngeal mask was necessary for a desaturation
episode, with an oxygen saturation value of less than 85%
lasted more than 3 minutes despite mask ventilation. In
this case the procedure was definitively stopped without
performing FNA. In all the other patients the blood pressure
never decreased under 90mmHg, the heart rate never
reduced to less than 50 pulses per minute and the oxygen
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Table 2: Observer’s scale for sedation and alertness (OSSA) score.
Score Responsiveness Eyes
5 Responds readily to name Clear and no ptosis
4 Lethargic response to name Glazed or mild ptosis (less than half of eye)
3 Responds only when called loudly or repeatedly Marked ptosis (more than half of eye)
2 Respond after mild prodding or shaking
1 Unresponsive to mild prodding or shaking
saturation never reduced under 85%. Mean postprocedural
observation time was 25min (range 18–45min).
5. Discussion
This study was designed to assess the safety and feasibility
of BPS administered by nonanaesthesiologist in EUS-FNA.
In our experience this protocol of sedation resulted to
be feasible and safe with an adequate training of medical
and nursing staﬀ. The guidelines of the American Society
of Gastrointestinal Endoscopy (ASGE) do not recommend
anesthesiological assistance for routine endoscopy in healthy
patients because of excessive costs [7]. Anesthesiological
associations have expressed concern about the use of propo-
fol by nonanaesthesiologists because of the possible need for
assisted ventilation [8]. A meta-analysis found that the use
of propofol by nonanaesthesiologists is not inferior to other
agents when used for EGD or ERCP/EUS and, compared to
traditional protocols of sedation, appears to lower the risk
of cardiopulmonary complications during colonoscopy [9].
In terms of eﬃcacy, recovery, and complications, the use
of propofol compared to standard sedation for endoscopy
oﬀers a more rapid induction and recovery from sedation
and faster discharge postprocedure [10–12]. Several studies
have shown that coadministration of benzodiazepine and/or
opioids during endoscopic procedures (EGD, colonoscopy,
and ERCP), also known as “balanced propofol sedation”
(BPS) enhances the sedative eﬀect of propofol and allows
titration of propofol tomoderate sedation [13]. This regimen
also allows total propofol dose to be reduced by about 50%
and makes propofol administration smoother by prolonging
the interval between doses [14]. Some reports failed to show
a reduction in propofol dose with the use of midazolam [15].
Comparing balanced propofol sedation with midazolam
alone for an ERCP, propofol is preferred by patients and
physicians and shortens recovery time [16, 17]. While its
use for EGD and colonoscopy has been extensively reported,
there are limited data describing the use of propofol sedation
for EUS [18, 19].
There are reports on propofol sedation for EUS admin-
istered by nonanesthesiologist physicians in boluses or by
target-controlled infusion. The safety of Nurses Adminis-
tered Propofol Sedation (NAPS) and the variables associated
with complications from its use for EUS have been also
described [20]. In the paper of Fatima et al., by using
univariate analysis, patient age, propofol dose, procedure
length, and EUS-FNA were not associated with the risk of
any sedation-related complications [21].
In our center there has been a strong interest in propofol
sedation in the last 4 years, in particular for colonoscopy
sedation. Since 2006, our staﬀ has performedmore than 5000
colonoscopies with BPS. Nevertheless, features of EUS and,
in particular, EUS-FNA procedure features are consistently
diﬀerent from colonoscopy. EUS-FNA is a diﬃcult and time-
consuming procedure. Upper endoscopic procedure are at
higher risk of respiratory complications as reported in the
literature [22]. Beside this, EUS instruments have a major
caliber compared to gastroscopes. An EUS-FNA procedure
lasts more than a gastroscopy or a colonoscopy and, for
safety reasons, during FNA a deeper level of sedation is often
required.
The current study was designed to assess the feasibility
and the safety of EUS-FNA performed with BPS sedation
administered by gastroenterologists. The administration of
propofol by gastroenterologist may be not as cost-eﬀective as
when it is administered by trained nurses, but, at present, it is
the only way allowed in our institution. During the study, an
anaesthesiologist was on call in case of adverse events. The
anaesthesiologist was free of other duties attending only to
nonclinical activities and ready to reach the endoscopic suite
in few minutes.
In our series we found no major complications. All
but one procedures were completed. Minor adverse events
occurred in 7 patients (6.3%) andwere easily treated. Overall,
5 patients (4.5%) had a decline in SBP <90mm Hg. All
episodes of hypotension were treated by increasing the rate
of IV fluids. The episodes of hypotension did not require
discontinuation of the procedure. The mean procedure time
in our study was 42.96 ±15min, not diﬀerent from reported
data [23]. In the current series, we found a decrease in SpO2
< 25% in 5 patients (4.5%), rapidly responsive to supple-
mental O2 administration in 2 patients; 3 patients (2.7%)
required assisted ventilation. One procedure (0.9%) was not
completed due to prolonged hypoxia treated by laryngeal
mask positioning. A single-center, prospective, randomized
trial comparing standard sedation versus propofol for ERCP
reported no cases of assisted ventilation in the arm of patients
receiving propofol [24]. In the studies where propofol was
administered by non-anaesthesiologist for outpatient under-
going EUS, no episodes of assisted ventilation were reported
[25, 26].Whether the continuous infusion of propofol lowers
the risk of respiratory adverse events compared to boluses
administration has never been investigated in the adult
population. Experience in the paediatric setting seems to
be slightly in favour of fractionated doses administration
[27].
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In our experience BPS can be a safe protocol of sedation
for healthy patients undergoing EUS-FNA. Comparing our
data to the literature there seems to be a diﬀerence in minor
complication rate. In particular we experienced the need for
mask ventilation in 3 patients, in one case with the use of
laryngeal mask. We also had in our series one perforation
(0.9%). This observational study was not designed to assess
the diﬀerence of complication between diﬀerent protocols
of sedation, but comparing data to an historical cohort of
patients that underwent EUS-FNA with anesthesiological
assistance a similar rate of minor complication was found. In
particular a perforation of the duodenal bulb was reported
in the cases with anesthesiological assistance. The diagnostic
yield of FNA in this series is similar to the literature data.
The major concern of propofol sedation is the respiratory
depression. The results of our series stress the importance of
the training in the airwaymanagement of the staﬀ involved in
BPS. Laryngeal mask use, in particular, should be considered
mandatory for the gastroenterologists administering this
kind of sedation.
In conclusion, our experience suggest a good profile of
safety of BPS administered by gastroenterologist in EUS-
FNA procedures. According to our results no significant
increase in the procedure-related complication rate was
registered and the diagnostic yield of FNA performed with
this protocol of sedation is not diﬀerent from the literature
data. Gastroenterologist administering propofol for EUS-
FNAmust be skilled in advanced life support, with particular
regard to airway management. Laryngeal mask, having a
shorter learning curve than orotracheal intubation, could be
the rescue procedure of choice in patients undergoing oxygen
desaturation nonresponsive to mask ventilation.
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